Physician profile
Mark A Cannon
NPI 1720169295
$19,083.12
in general payments reported to CMS, 2019-2025
27 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,331 · 2020: $2,292 · 2021: $2,827 · 2022: $2,534 · 2023: $2,451 · 2024: $3,270 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,074 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,073.67 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,233.17 | 2021-2025 | Vraylar |
| Alkermes, INC. | $2,205.43 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,785.39 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,628.51 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,580.00 | 2019-2025 | Fanapt, Hetlioz, Ponvory |
| Janssen Pharmaceuticals, INC | $1,539.16 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $1,414.68 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,353.72 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,105.60 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $889.89 | 2019-2022 | |
| Indivior INC. | $617.27 | 2019-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $605.27 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $529.63 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $437.69 | 2022-2024 | Qelbree, Qelbree |
| Allergan, INC. | $415.92 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $183.82 | 2020-2025 | Secuado |
| Merck Sharp & Dohme LLC | $127.60 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $113.18 | 2020-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $90.11 | 2019-2020 | |
| Eisai INC. | $50.09 | 2020 | |
| Noven Pharmaceuticals, INC. | $44.42 | 2021-2022 | |
| Almatica Pharma LLC | $32.20 | 2022-2025 | Loreev Xr |
| Neuronetics, INC. | $30.46 | 2022 | |
| Braeburn INC. | $22.08 | 2025 | Brixadi |
| Biogen, INC. | $21.04 | 2024 | |
| Adlon Therapeutics L.P. | $14.74 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.